Last Updated on January 3, 2024 by The Health Master
Venus Remedies has secured marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer and bladder carcinoma.
UK MHRA: The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK. MHRA is an executive agency, sponsored by the Department of Health and Social Care.
This marketing authorisation granted to Venus Pharma, the German subsidiary of Venus Remedies, will enable the company to offer its cancer drugs to the National Health Service (NHS) in the UK and neighbouring countries.
A company release informed that the registration for Cisplatin will also expedite the process of registering the oncology products of Venus Remedies in many other countries around the world which consider the UK as a reference country for fast-tracking registration and open opportunities for supplying unregistered products to several markets globally.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies said, “This year, the company intends to increase its sales in the UK to approximately two million Euros. We plan to achieve this by focusing on seven molecules which are already registered in the UK and augmenting their sales by 20 per cent on a year-on-year basis. We are also planning to add new molecules in the UK and other European countries, which will help us expand our operations and improve our sales in these markets.”
Venus Remedies has received many marketing authorisations from the UK MHRA for several drugs, including:
- Gemcitabine,
- Bortezomib,
- Meropenem,
- Docetaxel,
- Carboplatin,
- Ceftazidime.
“Obtaining marketing authorisations for our drugs in the UK will also help us strengthen our position in regulated markets in the Middle East, Latin America and other markets in Europe. Having product registrations from a recognised regulatory agency like the UK MHRA lends us a lot of credibility and enables us to streamline the registration process in other markets,” said Chaudhary.
He said the registration for Cisplatin in the UK would potentially help Venus Remedies in expediting the registration of its oncology product Paclitaxel, which is pending with the MHRA. “We are also about to apply for the marketing authorisation for Bendamustin, a chemotherapy medication used in the treatment of chronic lymphocytic leukaemia, in the UK,” he added.
The registration process for each drug is evaluated on a case-by-case basis, which differs from country to country, taking into account factors like safety, efficacy and quality.
Marksans Pharma gets UK MHRA nod for Diarrhoea medication
Future of Medical Device Regulation: Consultation by UK MHRA
CDSCO, UK MHRA to sign MoU on regulation of medicines, medical devices
USFDA gives approval for Icosapent Ethyl Capsules
Drug alert: 48 out of 1497 samples declared as NSQ in March 2023
USFDA issues directive to Sun Pharma for corrective action: Mohali
Drug recall: Sun Pharma, Hetero recall these drugs
Medical Device alert: USFDA identifies recall of this Medical Device as most serious
FDCA issued 2,267 new manufacturing licences in 2020-23: Gujarat
Pharmacy Inspectors appointed to check presence of Pharmacists at Medical Stores
Wet Granulation vs Dry Granulation: Understanding the Key Differences
Understanding GMP, cGMP, and WHO-GMP
Calibration of Laboratory Instruments
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
